PAI-1 antagonists: the promise and the peril.

Douglas E. Vaughan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


The plasminogen activator (i.e., fibrinolytic) system is one of the key endogenous defense mechanisms against intravascular thrombosis. Thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans, and have proven to be of value in the treatment of acute myocardial infarction and stroke. Although these agents are efficacious in the acute setting, they are not a viable option for long-term use. Net fibrinolytic activity is plasma is largely determined by the balance between tissue-type plasminogen activator (t-PA) and its natural, fast-acting inhibitor, plasminogen activator inhibitor-1 (PAI-1). The recent development of specific PAI-1 antagonists promises to expand the limits of understanding of the role of the fibrinolytic system in human disease, and to break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.

Original languageEnglish (US)
Pages (from-to)312-325
Number of pages14
JournalTransactions of the American Clinical and Climatological Association
StatePublished - 2011

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'PAI-1 antagonists: the promise and the peril.'. Together they form a unique fingerprint.

Cite this